NIH and Other Independent Studies Confirm Low Levels of BioAegis’ ‘Inflammation Regulator Protein,’ Gelsolin, Associated with COVID-19 Severity
February 02, 2021 14:05 ET | Source: BioAegis Therapeutics BioAegis Therapeutics Morristown, New Jersey, UNITED STATES
MORRISTOWN, N.J., Feb. 02, 2021 (GLOBE NEWSWIRE) BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases through a portfolio built around gelsolin technology, announced today that studies from three independent groups of investigators, including the NIH, have reported
that low levels of gelsolin are associated with severity and organ failure in COVID-19 patients, with the lowest pGSN levels seen in patients who subsequently died. BioAegis is currently conducting a Phase 2 clinical trial of recombinant human plasma gelsolin (rhu-pGSN) in severe COVID-19 patients to supplement gels